<DOC>
	<DOCNO>NCT00375128</DOCNO>
	<brief_summary>This study examine ability two new malaria vaccine ( FP9-PP MVA-PP ) prevent development malaria infection control exposure parasite . Volunteers trial receive vaccine precede trial VAC027.1 .</brief_summary>
	<brief_title>Sporozoite Challenge Polyprotein Vaccinees</brief_title>
	<detailed_description>Malaria infection kill 2 million people year . It major problem live endemic area traveller . There clearly great need safe effective malaria vaccine . The purpose study test clinical efficacy two candidate malaria vaccine ( FP9-PP MVA-PP ) . These live viral vector vaccine administer 'prime boost ' regime precede trial VAC027.1 . Volunteers expose 5 infective bite mosquito carry P. falciparum malaria . This trial : 1 . Measure efficacy time hour malaria exposure blood film positive malaria parasites 2 . Examine immunogenicity malaria infection 3 . Measure long term vaccine efficacy re-challenging protect volunteer 6 - 12 month later</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<criteria>Healthy nonpregnant adult age 18 50 year The vaccinated group subject receive vaccine regime describe group 6 7 VAC027.1 Resident near Oxford , UK duration challenge study For female , willingness practice effective contraception challenge study . Agreement refrain blood donation course study Written inform consent Willingness allow investigator access hospital General Practitioner medical note Willingness undergo HIV test Any deviation protocoldefined normal range biochemistry haematology blood test urine analysis Prior receipt investigational malaria vaccine ( unless administer VAC027.1 ) Use investigational nonregistered drug , live vaccine medical device study vaccine within 30 day precede dose study vaccine , plan use study period Administration chronic immunosuppressive drug immune modify drug within six month vaccination History malaria chemoprophylaxis chloroquine within 5 month prior plan challenge , Lariam within 6 week prior challenge , Riamet within 2 week prior challenge Any history malaria Travel malaria endemic country within previous 3 month prior plan challenge Planned travel malarious area study period Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection asplenia Evidence cardiovascular disease History cancer ( except basal cell carcinoma skin cervical carcinoma situ ) History haemoglobinopathy History diabetes mellitus Chronic active neurological disease require ongoing specialist supervision Chronic gastrointestinal disease require ongoing specialist supervision History &gt; 2 hospitalisation invasive bacterial infection ( pneumonia , meningitis ) Suspected know current alcohol abuse define alcohol intake great 42 unit every week Seropositive hepatitis B surface antigen ( HBsAg ) Seropositive hepatitis C virus ( antibody HCV ) Hepatomegaly , right upper quadrant abdominal pain tenderness Evidence serious psychiatric condition Any ongoing chronic illness require hospital specialist supervision Acute disease time enrolment Administration immunoglobulins and/or blood product within three month precede plan administration vaccine candidate Pregnant lactate female Female willing intend become pregnant study History severe reaction allergy mosquito bite PI assessment lack willingness participate comply requirement protocol History clinical evidence intravenous drug abuse Any find opinion investigator would significantly increase risk adverse outcome participate protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>Malaria</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Prime-boost</keyword>
	<keyword>Challenge</keyword>
</DOC>